DB 1314
Alternative Names: DB-1314Latest Information Update: 19 Sep 2024
At a glance
- Originator Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Sep 2024 DB 1314 is available for licensing as of 02 Sep 2024. https://www.dualitybiologics.com/partnership.html
- 14 Aug 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to August 2024
- 14 Aug 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical trial in Solid tumours released by Duality Biologics